Abstract 4527
Background
Malnutrition is very common in patients with cancer and is associated with an increase in morbidity and mortality, being directly responsible for death in up to 20% of cases. The presence of nutritional deficits in the initial stages of the tumor can condition tolerability to chemotherapy. The implementation of strategies to detect early malnutrition at all stages of the disease is essential to take measures to avoid their fatal consequences and to improve the quality of life of patients.
Methods
Analysis of the results obtained in the first nursing visit of 410 patients, between July 1, 2017 and May 1, 2018. Creation and completion of a standardized nursing assessment of all patients who come for the first time to a medical oncology consultation that includes: Nutritional status (MST - Malnutrition screening tool) Tumor and patient data BMI body mass index Changes in diet, types of changes ECOG Oncological treatment prescribed (standard or reduced dose).
Results
Patients with ≥2 MST are more likely to: have a higher age than the rest be men have a higher ECOG score have a reduced treatment dose have changed their diets.
Conclusions
The objective of the anaIysis is the identification of factors related to a higher probability of malnutrition in the first visit of nursing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract